Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Delos Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Delos Capital

Delos Capital

Operating

NYC-based Delos Capital is a private equity firm, investing in lower middle market US companies.

Location
New York City, NY, US
Founded
2009
Firm
Compare
Portfolio
Employees
Website

Investments

Sirius Therapeutics
Sirius Therapeutics

Total Raised

$60M

Rounds

1

Series B$60MOctober 2023
Instylla
Instylla

Total Raised

$63.5M

Rounds

3

Series C$30MAugust 2023
Ensoma
Ensoma

Total Raised

$205M

Rounds

3

Series B$50MMay 2023
Rejoni
Rejoni

Total Raised

$41.3M

Rounds

2

Series B$26.3MDecember 2022
Series A$15MSeptember 2020
Rgenta Therapeutics
Rgenta Therapeutics

Total Raised

$116.9M

Rounds

6

Series A$52MNovember 2022
Ostial
Ostial

Total Raised

$10.2M

Rounds

2

Series C$7.5MSeptember 2022
Exela Technologies
Exela Technologies
Public

Total Raised

$265M

Rounds

4

Post Ipo EquityJanuary 2022
OncoMyx Therapeutics
OncoMyx Therapeutics

Total Raised

$50M

Rounds

1

Series B$50MDecember 2021
Viron
Viron

Total Raised

$81M

Rounds

3

Series B$50MDecember 2021
Series A$25MJune 2019
Antios Therapeutics
Antios Therapeutics
Public

Total Raised

$200.4M

Rounds

4

Series B$75MNovember 2021
Series B$96MApril 2021
Series A$25MNovember 2018
Imperative Care
Imperative Care

Total Raised

$409M

Rounds

5

Series D$260MJuly 2021
Series C$85MDecember 2019
LifeQ
LifeQ

Total Raised

$47M

Rounds

2

Series A$47MMay 2021
Phanes Therapeutics
Phanes Therapeutics

Total Raised

$40M

Rounds

1

Series B$40MMay 2021
Curamir Therapeutics
Curamir Therapeutics

Total Raised

$10M

Rounds

1

Series A$10MSeptember 2019
Barricaid
Barricaid

Total Raised

$311.3M

Rounds

15

Series E$52MApril 2019
Debt Financing$28MMay 2017
Baronova
Baronova

Total Raised

$85.9M

Rounds

7

Series D$36.5MNovember 2015
Syndax Pharmaceuticals
Syndax Pharmaceuticals
Public

Total Raised

$803.6M

Rounds

16

Series C$80MAugust 2015
Atia Vision
Atia Vision

Total Raised

$111.1M

Rounds

8

Series B$3MMay 2015